Expansion of the B2B Business through Meiji Yakuhin’s CMO and CHC Businesses
First written in FY2022-Q2. 7 of 15 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.
5 other companies' latest entry also says "Other".
- FY2026Lower CMO sales and higher CHC salesAnnual report
「Net sales in the CMO business were ¥2,677 million, down 16.8% from the previous fiscal year. Net sales in the CHC business were ¥1,313 million, up 20.4%.」
Although 明治薬品's CMO business reported lower sales, the CHC business reported higher sales. In CMO, the Company is strengthening sales activities targeting pharmaceutical manufacturers in anticipation of the construction of a new plant. - FY2025-H1Decline in CMO and CHC revenueAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥1,648 million, down 25.8% year on year. With a view to constructing a new plant, sales activities targeting pharmaceutical manufacturers are being strengthened to expand contract projects over the medium to long term. Revenue from the company’s “CHC business,” which sells functional foods and pharmaceuticals through drugstore and other channels, was ¥513 million, down 18.7% year on year.」
Both the CMO and CHC businesses recorded lower revenue year on year. The CMO business is strengthening sales activities targeting pharmaceutical manufacturers with a view to constructing a new plant, while the CHC business is working to expand distribution of the drugstore-exclusive ニューモ hair-growth product. - FY2024AdvancedAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥4,646 million, up 10.9% year on year. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, the Company achieved stable orders and improved margins. Revenue from the company’s “CHC business,” which sells functional foods and pharmaceuticals through drugstore and other channels, was ¥1,130 million, up 31.9% year on year.」
明治薬品’s CMO revenue was ¥4,646 million and CHC revenue was ¥1,130 million, with both businesses continuing to record higher revenue. - FY2024-Q3AdvancedAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥3,395 million, up 10.5% year on year. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, the Company achieved stable orders and improved margins. The 2024 Noto Peninsula Earthquake in January 2024 affected product shipments due to production stoppages and water leakage, but operations have since returned to normal. Revenue from the company’s “CHC business,” which sells functional foods and pharmaceuticals through drugstore and other channels, was ¥909 million, up 16.8% year on year.」
The CMO business generated revenue of ¥3,395 million, up 10.5% year on year, while the CHC business generated revenue of ¥909 million, up 16.8% year on year. The CMO business achieved stable orders and improved margins, while the CHC business continues to expand sales. - FY2024-Q2AdvancedAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥2,220 million, up 11.2% year on year. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, the Company achieved stable orders and improved margins. Revenue from the company’s “CHC business,” which sells functional foods and pharmaceuticals through drugstore and other channels, was ¥632 million, up 30.5% year on year. Sales of new 明治薬品-branded products through drugstores are being expanded.」
明治薬品’s CMO business generated revenue of ¥2,220 million, up 11.2% year on year, while its CHC business generated revenue of ¥632 million, up 30.5% year on year. The CMO business achieved stable orders and improved margins, while the CHC business is expanding sales of new branded products. - FY2024-Q1AdvancedAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥1,151 million, up 29.0% year on year. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, the Company achieved stable orders and improved margins. Revenue from the company’s “CHC business,” which sells functional foods and pharmaceuticals through drugstore and other channels, was ¥377 million, up 20.9% year on year. Sales of new 明治薬品-branded products through drugstores are being expanded.」
CMO revenue increased 29.0% year on year against a backdrop of replacement demand, while CHC revenue increased 20.9% year on year. The CMO business achieved stable orders and improved margins, while the CHC business is expanding sales of new 明治薬品-branded products. - FY2023CMO revenue up, CHC revenue downAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥4,190 million, up 15.0% year on year. … Revenue from the company’s “CHC business,” which sells its functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥857 million, down 52.4% year on year.」
The CMO business recorded higher revenue due to replacement demand, price pass-through and the narrowing of contracted product lines, while the CHC business recorded a substantial decline, partly due to the impact of brand changes. - FY2023-Q2CMO revenue up, CHC revenue downAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品㈱, was ¥1,996 million, up 19.4% year on year. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, we passed higher costs through to contract prices and narrowed the range of products accepted for contract manufacturing to improve margins. Revenue from the company’s “CHC business,” which sells functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥484 million, down 44.3% year on year.」
The CMO business recorded higher revenue against a backdrop of replacement demand, while passing higher costs through to contract prices and narrowing the range of products accepted for contract manufacturing. The CHC business, however, declined 44.3% year on year. - FY2023-Q1AdvancedAnnual report
「Revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品株式会社, was ¥892 million. Amid rising replacement demand resulting from quality issues and manufacturing deficiencies at generic drug manufacturers, we have passed higher costs through to contract prices to improve margins. Revenue from the “CHC business,” which sells functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥312 million.」
CMO revenue was ¥892 million and CHC revenue was ¥312 million, as the Company responded to replacement demand for generic drugs and continued passing higher costs through to contract prices. - FY2022AdvancedAnnual report
「In the new manufacturing and sales channels, revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品株式会社, was ¥3,642 million, while revenue from the “CHC business,” which sells functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥1,801 million.」
明治薬品’s CMO business generated revenue of ¥3,642 million and its CHC business generated revenue of ¥1,801 million, establishing the full-year contribution from the new manufacturing and sales channels. - FY2022-Q3AdvancedAnnual report
「In the new manufacturing and sales channels, revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品株式会社, was ¥2,621 million, while revenue from the “CHC business,” which sells functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥1,335 million.」
明治薬品’s CMO business generated revenue of ¥2,621 million and its CHC business generated revenue of ¥1,335 million, increasing the contribution from the new manufacturing and sales channels. - FY2022-Q2First statedAnnual report
「In the new manufacturing and sales channels, revenue from the “CMO business,” which provides contract manufacturing of pharmaceuticals operated by 明治薬品株式会社, was ¥1,672 million, while revenue from the “CHC business,” which sells functional foods, pharmaceuticals and other products through drugstore and other channels, was ¥869 million.」
Following the acquisition of 明治薬品 as a subsidiary, the new manufacturing and sales channels for contract pharmaceutical manufacturing (CMO) and consumer healthcare (CHC) products for drugstores and other outlets were added to the consolidated results.